Kamada (KMDA) Research & Development (2012 - 2026)
Kamada's Research & Development was $2.2 million in the quarter ended Jun 30, 2026, down 31.7% from $3.22 million a year earlier but up 0.9% from the prior quarter.
Powered by 
Analysis
Kamada (KMDA) Research & Development (2012 - 2026) Analysis & Trends
On a trailing twelve-month basis, Kamada's Research & Development was $9.91 million through Jun 30, 2026, down 26.9% year-over-year; for the year ended Dec 31, 2025, it was $13 million, down 14.4% from the prior year.
- Research & Development shows a five-year compound annual growth rate of -0.9% (years ended Dec 2020 to Dec 2025).
- In earlier years, Research & Development was $15.19 million in the year ended Dec 31, 2024 (+9.0%), $13.93 million in the year ended Dec 31, 2023 (+5.8%), $13.17 million in the year ended Dec 31, 2022 (+16.0%) and $11.36 million in the year ended Dec 31, 2021 (-16.5%).
- Quarterly Research & Development has moved between $2.18 million (the quarter ended Mar 31, 2026) and $4.8 million (the quarter ended Jun 30, 2024) over five years.
- Compared with a year earlier, Research & Development was higher in two of the last eight quarters, with an average decline of 17.4%.
- The best year-over-year quarter for Research & Development over five years was the quarter ended Mar 31, 2022 (growth of 68.2%); the worst was the quarter ended Mar 31, 2026 (a decline of 48.6%).
- Per Business Quant data, KMDA's Research & Development in the three quarters before the quarter ended Jun 30, 2026 was $2.18 million (quarter ended Mar 31, 2026), $2.89 million (quarter ended Dec 31, 2025) and $2.64 million (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Kamada | 497.25 Mn | 206.31 Mn | 22.47 Mn | 2.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.20 Mn |
| Mar 31, 2026 | 2.18 Mn |
| Dec 31, 2025 | 2.89 Mn |
| Sep 30, 2025 | 2.64 Mn |
| Jun 30, 2025 | 3.22 Mn |
| Mar 31, 2025 | 4.25 Mn |
| Dec 31, 2024 | 2.67 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 4.80 Mn |
| Mar 31, 2024 | 4.30 Mn |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.18 Mn |
| Jun 30, 2023 | 4.28 Mn |
| Mar 31, 2023 | 3.23 Mn |
| Dec 31, 2022 | 2.99 Mn |
| Sep 30, 2022 | 3.12 Mn |
| Jun 30, 2022 | 2.64 Mn |
| Mar 31, 2022 | 4.42 Mn |
| Dec 31, 2021 | 3.45 Mn |
| Sep 30, 2021 | 2.55 Mn |
API Access
Kamada Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=KMDA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "KMDA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=KMDA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();